MWNA
ACIU icon

Marshall Wace North America’s AC Immune ACIU Stock Holding History

Marshall Wace North America’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,374
Closed -$29K – 1181
2019
Q4 		$29K Sell
3,374
-5,578
-62% -$37.2K ﹤0.01% 1186
2019
Q3 		$44K Sell
8,952
-8,156
-48% -$43.7K ﹤0.01% 1174
2019
Q2 		$95K Buy
17,108
+1,272
+8% +$6.48K ﹤0.01% 1072
2019
Q1 		$80K Buy
15,836
+13,654
+626% +$86.8K ﹤0.01% 1158
2018
Q4 		$21K Buy
+2,182
New +$20.6K ﹤0.01% 1389

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Marshall Wace North America's ACIU Position: Q1 2020 in Review

Marshall Wace North America sold out of AC Immune (ACIU) in Q1 2020, closing a stake of 3,374 shares — an estimated $29K sold.

Marshall Wace North America first reported a position in ACIU in Q4 2018 and held it in 5 quarters. The position peaked at $95K in Q2 2019. 50 funds tracked by Wall St. Rank hold ACIU as of Q1 2020.

  • Marshall Wace North America reported no remaining AC Immune position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 3,374 AC Immune shares in Q1 2020, an estimated $29K.
  • Marshall Wace North America first reported a position in AC Immune in Q4 2018 and held it in 5 quarters.
  • Marshall Wace North America's AC Immune position peaked at $95K in Q2 2019.
  • 50 funds tracked by Wall St. Rank held AC Immune as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.